Murakami M, Hosoi Y, Negishi T, Kamiya Y, Miyashita K, Yamada M, Iriuchijima T, Yokoo H, Yoshida I, Tsushima Y, Mori M
First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
J Clin Invest. 1996 Nov 15;98(10):2228-34. doi: 10.1172/JCI119032.
Thymic size and density were studied in 23 untreated patients with Graves' disease and 38 control subjects using computed tomography. Both thymic size and density were higher in untreated patients with Graves' disease than in control subjects in the age-matched group. After treatment with antithyroid drugs, both thymic size and density were significantly reduced, with a concomitant decrease in thyrotropin receptor antibodies. PCR of human thymic cDNA using primers for human thyrotropin receptor amplified a fragment in a size expected for the receptor, and its nucleotide sequence was identical to human thyrotropin receptor cDNA in the thyroid. Northern blot analysis of human thymic poly(A)+ RNA demonstrated the presence of the full length form of thyrotropin receptor mRNA. Western blot analysis of human thymic membrane using anti-thyrotropin receptor peptide antibodies demonstrated a band of 100 kD that was also observed in the thyroid membrane. Immunohistochemistry of thymic tissue using mouse antihuman thyrotropin receptor monoclonal antibodies demonstrated the immunostaining of epithelial cells. These results indicate that thymic hyperplasia is apparently associated with Graves' disease and suggest that thymic thyrotropin receptor may act as an autoantigen that may be involved in the pathophysiology of development of Graves' disease.
利用计算机断层扫描技术,对23例未经治疗的格雷夫斯病患者和38名对照者的胸腺大小和密度进行了研究。在年龄匹配组中,未经治疗的格雷夫斯病患者的胸腺大小和密度均高于对照者。使用抗甲状腺药物治疗后,胸腺大小和密度均显著降低,同时促甲状腺素受体抗体也减少。用人促甲状腺素受体引物对人胸腺cDNA进行PCR扩增,得到了预期大小的受体片段,其核苷酸序列与甲状腺中的人促甲状腺素受体cDNA相同。对人胸腺多聚腺苷酸加尾RNA进行Northern印迹分析显示存在全长形式的促甲状腺素受体mRNA。用人促甲状腺素受体肽抗体对人胸腺膜进行蛋白质印迹分析,显示出一条100 kD的条带,该条带在甲状腺膜中也能观察到。用小鼠抗人促甲状腺素受体单克隆抗体对胸腺组织进行免疫组织化学分析,显示上皮细胞有免疫染色。这些结果表明胸腺增生显然与格雷夫斯病有关,并提示胸腺促甲状腺素受体可能作为自身抗原参与格雷夫斯病发生发展的病理生理过程。